Skip to main content

Table 2 Grade ≥ 3 adverse events occurring in randomized phase III trials of bevacizumab in advanced ovarian cancer

From: Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review

Grade ≥ 3 AE, %

GOG-0218[21]

ICON7[22]

OCEANS[41]

AURELIA[26]

CP + placebo

CP + Bev

CP + Bev → Bev

CP

CP + Bev → Bev

CG + placebo

CG + Bev

CTx

CTx + Bev

(n = 601)

(n = 607)

(n = 608)

(n = 753)

(n = 745)

(n = 233)

(n = 247)

(n = 182)

(n = 179)

Neutropenia

57.7a

63.3a

63.3a

15

17

–

–

–

–

Pain

41.6b

41.5b

47.0b

–

–

–

–

–

–

Thrombocytopenia

–

–

–

2

3

34

40

–

–

Hypertension

7.2b

16.5b

22.9b

<1

6

0.4

17.8

–

–

VTE

5.8c

5.3c

6.7c

2

4

–

–

4

3

Febrile neutropenia

3.5c

4.9c

4.3c

2

3

–

–

1

1

Proteinuria

0.7

0.7

1.6

<1

1

0.9

9.7

–

–

Bleeding (non-CNS)

0.8

1.3

2.1

<1

1

0.9

5.7

1

1

Wound healing complications

2.8c

3.6c

3.0c

<1

1

–

–

–

–

ATE

0.8c

0.7c

0.7c

1

3

–

–

0

2

GI events

1.2b

2.8b

2.6b

<1

1

0

0

–

–

Epistaxis

–

–

–

–

–

0.4

4.9

–

–

Abscess/fistula

–

–

–

1

1

0.4c

1.6c

–

–

RPLS

0

0.2c

0.2c

0

0

0

0.8c

0

1

CHF

–

–

–

<1

<1

–

–

1

1

CNS bleeding

0

0

0.3c

0

<1

–

–

–

–

  1. AE = adverse event. ATE = arterial thromboembolic event. Bev = bevacizumab. C = carboplatin. CHF = congestive heart failure. CNS = central nervous system. CTx = chemotherapy. G = gemcitabine. GI = gastrointestinal. P = paclitaxel. RPLS = reverse posterior leukoencephalopathy syndrome. VTE = venous thromboembolic event.
  2. aGrade ≥ 4.
  3. bGrade ≥ 2.
  4. cAll grades.